Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TVGN-520
- Development stage
- Unknown
- Lead developer
- Tevogen Bio
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
TVGN-520 is an investigational allogeneic, off-the-shelf cytotoxic CD8+ T lymphocyte (CTL) therapy developed by Tevogen Bio using its proprietary ExacTcell™ platform. The therapy is designed to treat HPV-driven malignancies by targeting specific antigens across the Human Papillomavirus (HPV) genome. Unlike traditional CAR-T or TCR-T therapies, TVGN-520 utilizes genetically unmodified T cells that leverage natural immune recognition to identify and eliminate cancerous cells expressing HPV proteins. This approach aims to provide a targeted treatment for various HPV-associated cancers while potentially offering a better safety profile and broader applicability as an allogeneic product. The therapy is currently being evaluated in Phase 1 clinical development.
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on TVGN-520.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TVGN-520.